Mme Docteur CATHERINE PRAT-BENOUAICH

RhumatologueMédecins généralistes et spécialistes👤 Libéral intégral

📍 Auzeville-Tolosane (31)Libéral💶 Secteur 2RPPS 10100120913

✨ Profil synthétique

IA · 14/05/2026

Mme Docteur Catherine Prat-Benouaich est une rhumatologue exerçant à Auzeville-Tolosane. Ses publications sur PubMed couvrent divers sujets, notamment la pédiatrie, les essais cliniques et la santé mentale. Elle a également publié des cas cliniques et des revues générales.

Expertises présumées

Rhumatologie pédiatrique
Fatigue chronique
Santé mentale en rhumatologie
Essais cliniques en rhumatologie
Cas cliniques complexes
Revue de littérature médicale
Méta-analyse en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Diplômes

🎓 DES & spécialité ordinale

DES Rhumatologie
Rhumatologie (SM)

🎓 Diplômes

DE Docteur en médecine

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second-line docetaxel: A randomized trial

Health science reports · 2024

📚 8 citations🎯 RCR 2.21Top 24% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractBackgroundIn this study, we investigated whether the association of curcumin and docetaxel among advanced and metastatic breast cancer patients in first or second‐line treatment potentiated the objective response rate.Patients/MethodsA multicentre, randomized, open label, phase‐II study was conducted and included 42 patients from July 2009 to January 2017. The primary endpoint was the objective response rate of the docetaxel‐curcumin combination in comparison with docetaxel alone. The secondary endpoints were the assessment of clinical benefit, overall survival, time‐to‐progression, progression‐free survival, compliance, and safety. An interim analysis was planned to evaluate safety and efficacy.ResultsIn this interim analysis conducted on 37 patients (19 in the control group vs. 18 in the experimental group), no difference was observed for the objective response rate (p = 0.25, control 73.7% vs. experimental 55.6%). Concerning clinical benefit, overall survival and time‐to‐progression, we also failed to show any difference between the two arms. A slight tendency towards longer progression‐free survival at 12 months after randomization was observed in the curcumin group (65.5% vs. 41.4%) but this difference did not reach significance (p = 0.14).ConclusionIn this study, we showed for the first time that adding oral curcumin for advanced and metastatic breast cancer patients treated with first or second‐line docetaxel was not efficacious, although safe. Consequently, this study was stopped for reasons of futility. Further studies with a larger number of patients, a different curcumin preparation, a longer treatment period and a pharmacokinetic evaluation of curcumin are needed to explore the real efficacy of this compound.

Advances in nanoparticle-based doxorubicin delivery: precision strategies for targeted treatment of triple-negative breast cancer

Discover nano · 2025

📚 6 citations🎯 RCR 2.16🔓 Open Access📄 PDF gratuit ↗

Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program

Journal of leukocyte biology · 2024

📚 4 citations🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Mepolizumab, an anti-interleukin-5 antibody, has been proven a safe and effective glucocorticoid (GC)-sparing drug for many patients with nonclonal hypereosinophilic syndrome (HES) and is now approved in many countries. It remains unclear, however, which patients are most likely to benefit from therapy and whether the currently approved dosing regimen is appropriate for all. This observational retrospective study included all patients with HES who were enrolled in the MHE104317 compassionate use program (CUP) in our center. Patient and disease characteristics, mepolizumab dosing, and both clinical and hematological responses to treatment were collected from medical files. Treatment responses and mepolizumab dosing requirements were analyzed according to disease characteristics. Eighteen patients with HES were enrolled in the CUP, of whom nine are still on treatment. The median duration of exposure to mepolizumab was 45 mo (maximum 18 yr). A lower number of affected organs, requirement for GC dosing ≤10 mg prednisone-equivalent, and single-organ HES were associated with a higher likelihood of complete response. Lymphocytic variant HES (L-HES) was less treatment-responsive, leading to withdrawal and/or requiring higher mepolizumab dosing to achieve some degree of disease control. In contrast, all patients with single-organ disease had a complete response that could often be maintained despite increasing between-dose intervals. Few potentially treatment-related adverse events were observed despite prolonged exposure. This study confirms the efficacy and safety of mepolizumab in HES, although patients with L-HES rarely experience a complete response. In contrast, patients with single-organ disease affecting the lungs are often super-responders, and decreasing mepolizumab dosing may be attempted.

Cookies & analyse de trafic

Docteur CATHERINE PRAT-BENOUAICH

Pourquoi vous devez consulter ce praticien

Diplômes

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal31

Pédiatrie4

Case report / série3

Essai clinique3

Revue générale3

Santé mentale / fatigue3

Revue / méta-analyse2

Vraie vie / RWE2

Activité physique / Rééducation1

Corticothérapie1

Épidémiologie & registres1

Gériatrie1

Lupus1

Pharmacovigilance1

SAPL1

Vascularites des gros vaisseaux1

Partager cette fiche